SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported) November 15, 1999 -----------------
OXIS INTERNATIONAL, INC. - ---------------------------------------------------------------------------------------------------- Delaware 0-8092 94-1620407 - ---------------------------------------------------------------------------------------------------- (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Incorporation) Number) 6040 N. Cutter Circle, Suite 317 Portland, OR 97217-3935 - ---------------------------------------------------------------------------------------------------- (Address of Principal Executive Offices) Registrant's telephone number, including area code. (503) 283-3911 ------------------------------------------------- ____________________________________________________________________________________________________ (Former Name or Former Address if Changes Since Last Report)
Item 2. Acquisition or Disposition of Assets -------------------------------------------- On November 15, 1999, OXIS International, Inc. ("OXIS") entered into an Agreement with Enzon, Inc. ("Enzon") pursuant to which OXIS assigned to Enzon the rights to its patents relating to polyalkylene glycols. OXIS retained a non-exclusive perpetual paid-up license under these patents for PEG conjugated superoxide dismutase. The Agreement is filed herewith as Exhibit 10.1. In exchange for the assignment, OXIS received an up-front cash payment of $600,000, and will receive an additional cash amount of $225,000 upon FDA approval of the first U.S. product covered by these patents. Additionally, Enzon will pay a royalty based on net sales of High Molecular Weight polyalkylene glycol products it hereinafter chooses to develop and sell, which are covered by these OXIS patents. This Agreement supercedes a July 1997 Non- Exclusive License Agreement between these parties relating to these OXIS patents. 2 Item 7. Financial Statements, Pro Forma Financial Information and Exhibits ------------------------------------------------------------------ (c) Exhibits -------- Exhibit 10.1 Agreement dated October 15, 1999, by and between OXIS International, Inc. and Enzon, Inc. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November 24, 1999 OXIS INTERNATIONAL, INC. (Registrant) /s/ Jon S. Pitcher ----------------------------- Chief Financial Officer and Vice President 4 EXHIBIT INDEX Page Exhibit Number - ------- ------ Exhibit 10.1 Agreement dated October 15, 1999, by and between OXIS International, Inc. and Enzon, Inc. 6 5